Companies are scrambling to get into the immunotherapy market, which experts think could eventually be worth up to $40bn (£26bn) a year in sales
The new generation of drugs hailed as once-in-a-generation advance in treatment for cancer patients is also viewed as good news for the pharmaceutical industry - just when analysts had started to voice concerns that the pipeline of blockbuster treatments in development was starting to run dry.
Immunotherapy treatments, which use the body’s immune system to attack cancerous cells, could be as revolutionary as the arrival of chemotherapy was in the 1940s - and big pharma companies have been scrambling to get into a market that experts think could eventually be worth up to $40bn (£26bn) a year in sales.
Related: Immunotherapy: the big new hope for cancer treatment
Continue reading...
No comments:
Post a Comment